drugset
drugset / Trial / NCT00483899

Examine the Effect of Repeat Inhaled Doses of GW870086X on Lung Function in Mild Asthmatic Male Subjects

NCT00483899 ↗

Phase 1 Completed 20 enrolled GlaxoSmithKline
RandomizedCrossoverDouble-blindTreatment

Summary

This study was designed to look at safety aspects and effects of repeat inhaled doses of GW870086X in mild asthmatics to develop this drug for its use in asthma and chronic obstructive pulmonary disease (COPD)

Timeline

Start
2005-10-07
Primary completion
2006-12-15
Completion
2006-12-15

Drugs

EvaluationDrugModalityDoseRoute
Subject GW870086 Small molecule 0.25 mg Inhaled
Subject GW870086 Small molecule 0.5 mg Inhaled
Subject GW870086 Small molecule 1 mg Inhaled
Subject GW870086 Small molecule 1.5 mg Inhaled
Subject GW870086 Small molecule 2 mg Inhaled
Subject GW870086 Small molecule 3 mg Inhaled
Subject GW870086 Small molecule 6 mg Inhaled

Indications

asthma